JP6495270B2 - 神経保護ペプチドを含有する医薬組成物 - Google Patents

神経保護ペプチドを含有する医薬組成物 Download PDF

Info

Publication number
JP6495270B2
JP6495270B2 JP2016527328A JP2016527328A JP6495270B2 JP 6495270 B2 JP6495270 B2 JP 6495270B2 JP 2016527328 A JP2016527328 A JP 2016527328A JP 2016527328 A JP2016527328 A JP 2016527328A JP 6495270 B2 JP6495270 B2 JP 6495270B2
Authority
JP
Japan
Prior art keywords
peptide
pharmaceutical composition
glutamate
peptides
protamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016527328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540739A (ja
JP2016540739A5 (enExample
Inventor
メローニ、ブルーノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Australia
Original Assignee
University of Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013904197A external-priority patent/AU2013904197A0/en
Application filed by University of Western Australia filed Critical University of Western Australia
Publication of JP2016540739A publication Critical patent/JP2016540739A/ja
Publication of JP2016540739A5 publication Critical patent/JP2016540739A5/ja
Application granted granted Critical
Publication of JP6495270B2 publication Critical patent/JP6495270B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
JP2016527328A 2013-10-30 2014-10-30 神経保護ペプチドを含有する医薬組成物 Active JP6495270B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2013904197A AU2013904197A0 (en) 2013-10-30 Neuroprotective peptides
AU2013904197 2013-10-30
AU2014902319A AU2014902319A0 (en) 2014-06-17 Neuroprotective peptides
AU2014902319 2014-06-17
PCT/AU2014/050326 WO2015061856A1 (en) 2013-10-30 2014-10-30 Neuroprotective peptides

Publications (3)

Publication Number Publication Date
JP2016540739A JP2016540739A (ja) 2016-12-28
JP2016540739A5 JP2016540739A5 (enExample) 2017-10-19
JP6495270B2 true JP6495270B2 (ja) 2019-04-03

Family

ID=53003020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016527328A Active JP6495270B2 (ja) 2013-10-30 2014-10-30 神経保護ペプチドを含有する医薬組成物

Country Status (7)

Country Link
US (3) US20160250285A1 (enExample)
EP (1) EP3063168B1 (enExample)
JP (1) JP6495270B2 (enExample)
CN (1) CN106170491B (enExample)
DK (1) DK3063168T3 (enExample)
ES (1) ES2724932T3 (enExample)
WO (1) WO2015061856A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303063B2 (en) * 2011-03-18 2016-04-05 Duke University Peptide compounds for suppressing inflammation
WO2014202834A1 (en) * 2013-06-18 2014-12-24 University Of Helsinki Protamine in treatment of neuronal injuries
CN106170491B (zh) 2013-10-30 2020-07-24 阿尔杰妮卡治疗学有限公司 神经保护肽
ES2896224T3 (es) * 2016-06-23 2022-02-24 Japan Science & Tech Agency Composición farmacéutica que comprende arginina para su uso en el tratamiento de la enfermedad de PolyQ
US10774122B2 (en) * 2017-03-21 2020-09-15 The Regents Of The University Of Michigan ERG targeted therapy
AU2018247561A1 (en) * 2017-04-02 2020-11-26 Interk Peptide Therapeutics Limited Compositions and methods for prophylaxis or treatment of pain
JP2022505101A (ja) * 2018-10-18 2022-01-14 ファンダメンタル ファーマ ゲーエムベーハー Ｎｍｄａ受容体媒介毒性を調節するための新規の方法
JP2021116244A (ja) * 2020-01-23 2021-08-10 有機合成薬品工業株式会社 高純度プロタミン硫酸塩
CN115385987B (zh) * 2021-05-19 2024-08-02 中山大学 一种抗鱼类神经坏死病毒的穿膜肽及其应用
JP2023022363A (ja) * 2021-08-03 2023-02-15 国立大学法人北海道大学 細胞保護用剤
CN114533874B (zh) * 2022-01-27 2023-12-29 北京和舆医药科技有限公司 Psd-95 gk结构域作为神经保护靶点的用途
WO2026099761A1 (en) 2024-11-06 2026-05-15 Salem Yahya Ahmed Peptides
CN119563880B (zh) * 2025-01-24 2025-07-15 浙江工业大学 一种多肽负载沙棘果油微囊粉及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4684624A (en) 1983-12-22 1987-08-04 Yoshio Hosobuchi Method of treating cerebral ischemia
US5559095A (en) 1989-11-22 1996-09-24 Neurex Corporation Delayed treatment method of reducing ischemia-related neuronal damage
WO1998041223A1 (en) 1997-03-20 1998-09-24 The Regents Of The University Of California N-methyl-d-aspartate receptor channel blockers and method for identifying such
US6605115B1 (en) * 1999-06-05 2003-08-12 Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
DE60230071D1 (de) 2002-06-14 2009-01-08 Monier Tadros Methode für die herstellung von protamin
GB0223193D0 (en) * 2002-10-07 2002-11-13 Ludwig Inst Cancer Res Polypeptide
JP2007526316A (ja) 2004-03-01 2007-09-13 ルーメン セラピューティックス リミテッド ライアビリティ カンパニー 疾患を処置するための組成物および方法
EP1957093B1 (en) 2005-08-29 2017-04-12 SHASHOUA, Victor E. Neuroprotective and neurorestorative methods and compositions
PL1969003T3 (pl) 2005-12-14 2011-05-31 Herantis Pharma Plc Zastosowanie białka czynnika neurotroficznego
US20070269892A1 (en) * 2006-05-18 2007-11-22 Nastech Pharmaceutical Company Inc. FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
WO2008054544A2 (en) * 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
GB0702022D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
GB0702020D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
WO2008133929A2 (en) * 2007-04-24 2008-11-06 Yale University Cell permeable miniature proteins
KR20090034239A (ko) * 2007-10-02 2009-04-07 재단법인서울대학교산학협력재단 골형성 촉진용 세포투과성 융합 단백질 및 그 용도
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
CA2990678C (en) 2009-11-06 2021-08-31 The J. David Gladstone Institutes Methods and compositions for modulating tau levels
NO2504357T3 (enExample) 2009-11-23 2017-12-30
US20120301446A1 (en) 2010-02-04 2012-11-29 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification for treatment of neurological disorders
WO2012050673A1 (en) * 2010-10-14 2012-04-19 Wisconsin Alumni Research Foundation Methods for the treatment of x-linked hypophosphatemia and related disorders
WO2013076666A1 (en) * 2011-11-23 2013-05-30 Newsouth Innovations Pty Limited Antimicrobial peptides and uses thereof
CA2857287A1 (en) 2011-11-29 2013-06-06 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of active agents across the blood-brain barrier
EP2872160A4 (en) * 2012-04-17 2015-11-25 Univ Brown NERVO-PROTECTING COMPOSITION AND USE METHOD
WO2013163423A1 (en) * 2012-04-25 2013-10-31 Musc Foundation For Research Development Compositions and methods for wound healing and tissue repair
EP2986115A4 (en) 2013-02-06 2017-03-01 Academia Sinica Antimicrobial peptides derived from hepatitis b virus core protein arginine-rich domain
WO2014202834A1 (en) * 2013-06-18 2014-12-24 University Of Helsinki Protamine in treatment of neuronal injuries
CN106170491B (zh) 2013-10-30 2020-07-24 阿尔杰妮卡治疗学有限公司 神经保护肽

Also Published As

Publication number Publication date
EP3063168B1 (en) 2019-03-06
US20180326001A1 (en) 2018-11-15
EP3063168A4 (en) 2017-03-22
DK3063168T3 (en) 2019-04-15
JP2016540739A (ja) 2016-12-28
EP3063168A1 (en) 2016-09-07
CN106170491A (zh) 2016-11-30
US12303550B2 (en) 2025-05-20
US20160250285A1 (en) 2016-09-01
US20220111003A1 (en) 2022-04-14
US11229678B2 (en) 2022-01-25
CN106170491B (zh) 2020-07-24
WO2015061856A1 (en) 2015-05-07
ES2724932T3 (es) 2019-09-17

Similar Documents

Publication Publication Date Title
US12303550B2 (en) Neuroprotective peptides
JP4116062B2 (ja) 環状接着阻害剤
US20030004112A1 (en) Cell-permeable protein inhibitors of calpain
JP2022513223A5 (enExample)
MXPA96004100A (en) Cyclic compounds, adhes inhibitors
WO2010013012A2 (en) Novel polypeptides and uses thereof
KR101913285B1 (ko) 세포자멸사의 억제제 및 이의 용도
CA3040645A1 (en) Peptide-based non-proteinaceous cargo delivery
JP2000510102A (ja) 環状接着阻害剤
CN114605497A (zh) 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途
JP2026041880A (ja) 細胞透過性ペプチド変異体およびその用途
US20100004165A1 (en) Novel Protein Transduction Domains and Uses Therefor
CN110799547B (zh) 用于治疗、改善或预防神经系统相关病症的化合物及其用途
JP7112753B2 (ja) Ｄｓｇ２由来ペプチド
MacDougall et al. In vitro cellular uptake and neuroprotective efficacy of poly-arginine-18 (R18) and poly-ornithine-18 (O18) peptides: critical role of arginine guanidinium head groups for neuroprotection
CA2444626A1 (en) Retrocyclins: antiviral and antimicrobial peptides
US20260091078A1 (en) Oligopeptide that inhibits angiogenesis and vascular function
WO2008107722A2 (en) Peptides, compositions and uses thereof
WO2003004600A2 (en) Improvement of viral uptake into cells and tissues
CN113773369B (zh) 有抗凝血和抗血小板活性的多靶点化合物及制法和用途
US20170114093A1 (en) Methods of Treatment and Prevention of Disease by Arginine-rich Compositions that Induce Cytoprotection and Neuroprotection
KR20250077606A (ko) 변형된 카베올린-1 펩타이드 제형 그리고 이의 제조 방법 및 용도
WO2002072131A1 (fr) Médicaments contre des affections hépatiques

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170908

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190306

R150 Certificate of patent or registration of utility model

Ref document number: 6495270

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250